Responses
Clinical/translational cancer immunotherapy
Original research
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146
Compose a Response to This Article
Other responses
No responses have been published for this article.
